CL2015000655A1 - Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas - Google Patents

Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas

Info

Publication number
CL2015000655A1
CL2015000655A1 CL2015000655A CL2015000655A CL2015000655A1 CL 2015000655 A1 CL2015000655 A1 CL 2015000655A1 CL 2015000655 A CL2015000655 A CL 2015000655A CL 2015000655 A CL2015000655 A CL 2015000655A CL 2015000655 A1 CL2015000655 A1 CL 2015000655A1
Authority
CL
Chile
Prior art keywords
therapeutic
methods
therapeutic agent
nanoparticles
nanoparticula
Prior art date
Application number
CL2015000655A
Other languages
English (en)
Inventor
Maria Figueiredo
Erick Peeke
David Dewitt
Geen Hoven Christina Van
Greg Troiano
James Wright
Young-Ho Song
Hong Wang
Original Assignee
Bind Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bind Therapeutics Inc filed Critical Bind Therapeutics Inc
Publication of CL2015000655A1 publication Critical patent/CL2015000655A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

NANOPARTICULA TERAPEUTICA QUE COMPRENDE UN ACIDO HIDROFOBICO, UN AGENTE TERAPEUTICO BASICO CON UN NITROGENO PROTONABLE Y UN COPOLIMERO DIBLOQUE DE ACIDO POLI(LACTICO)POLIETILENGLICOL; COMPOSICION FARMACEUTICAMENTE ACEPTABLE, METODO PARA TRATAR EL CANCER; Y PROCESO PARA PREPARAR UN NANOPARTICULA TERAPEUTICA
CL2015000655A 2012-09-17 2015-03-17 Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas CL2015000655A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702014P 2012-09-17 2012-09-17
US201261732510P 2012-12-03 2012-12-03
US201261733627P 2012-12-05 2012-12-05

Publications (1)

Publication Number Publication Date
CL2015000655A1 true CL2015000655A1 (es) 2015-11-27

Family

ID=49274869

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000655A CL2015000655A1 (es) 2012-09-17 2015-03-17 Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas

Country Status (23)

Country Link
US (4) US20140178475A1 (es)
EP (1) EP2895146A1 (es)
JP (2) JP2015529683A (es)
KR (1) KR20150056619A (es)
CN (1) CN104822370A (es)
AU (1) AU2013315125B2 (es)
BR (1) BR112015005878A2 (es)
CA (1) CA2885022A1 (es)
CL (1) CL2015000655A1 (es)
CR (1) CR20150189A (es)
DO (1) DOP2015000061A (es)
EA (1) EA201590586A1 (es)
EC (1) ECSP15013179A (es)
GT (1) GT201500063A (es)
HK (1) HK1211468A1 (es)
IL (1) IL237779A0 (es)
MX (1) MX363147B (es)
NI (1) NI201500036A (es)
NZ (1) NZ705985A (es)
PE (1) PE20150997A1 (es)
PH (1) PH12015500561A1 (es)
SG (1) SG11201502008WA (es)
WO (1) WO2014043625A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2462090T5 (es) 2008-06-16 2017-07-12 Pfizer Inc. Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
ES2721898T3 (es) 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
EA201290499A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
WO2013110028A1 (en) 2012-01-19 2013-07-25 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
CN104394891B (zh) 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2871745C (en) 2012-05-03 2023-01-24 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
BR112015005940A2 (pt) * 2012-09-17 2017-07-04 Bind Therapeutics Inc processo para a preparação de nanopartículas terapêuticas
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
RS56362B1 (sr) 2013-09-16 2017-12-29 Astrazeneca Ab Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
HUE047934T2 (hu) 2014-02-13 2020-05-28 Pfizer Terápiás szert tartalmazó terápiás nanorészecskék, ezek elõállítása és alkalmazása
US11016089B2 (en) * 2014-02-17 2021-05-25 Board Of Trustees Of The University Of Arkansas Nanocomposites and nanoagents for detection and treatment of a target of interest and methods of making and using same
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
EP3160449B1 (en) 2014-06-24 2023-12-13 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
CN110478495A (zh) 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
ES2942260T3 (es) 2014-09-14 2023-05-31 Tel Hashomer Medical Res Infrastructure & Services Ltd Ligandos sintéticos de receptores de somatostatina
EP4445952A2 (en) * 2014-12-15 2024-10-16 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN106366897B (zh) * 2015-07-22 2021-06-04 陶氏环球技术有限责任公司 用于制备具有耐湿和耐腐蚀性涂层的环境固化组合物及使用方法
US10131813B2 (en) * 2015-07-22 2018-11-20 Dow Global Technologies Llc Ambient cure compositions for making coatings having humidity and corrosion resistance and methods of use
US10669429B2 (en) * 2015-07-22 2020-06-02 Dow Global Technologies Llc Ambient cure compositions for making coatings having humidity and corrosion resistance and methods of use
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3368021A4 (en) * 2015-10-30 2019-07-31 Pfizer Inc THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT, AND METHODS OF MAKING AND USING SAME
AU2016353355B9 (en) 2015-11-12 2022-09-29 Graybug Vision, Inc. Aggregating microparticles for therapy
WO2017089942A1 (en) * 2015-11-25 2017-06-01 Pfizer Inc. Therapeutic nanoparticles comprising an antibiotic and methods of making and using same
WO2017147240A1 (en) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Hsp90 targeted conjugates and particles and formulations thereof
EP3432864B1 (en) * 2016-03-22 2020-05-06 Pfizer Inc Process for preparing therapeutic nanoparticles
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CA3028751A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
RU2019133337A (ru) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. Лекарственные средства и композиции для лечения глазных нарушений
EP3621659B1 (en) 2017-05-09 2024-07-24 Dignity Health Drug delivery composition and method of fabrication
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US20200268679A1 (en) * 2017-11-03 2020-08-27 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
CN113840926A (zh) * 2019-03-19 2021-12-24 阿克丘勒斯治疗公司 脂质包封的rna纳米颗粒的制备方法
JOP20210305A1 (ar) * 2019-05-16 2023-01-30 Aerovate Therapeutics Inc صيغ إيماتينيب وتصنيعها واستخداماتها
WO2021178920A1 (en) 2020-03-05 2021-09-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9
EP4117631A1 (en) * 2020-03-11 2023-01-18 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
JP2023542643A (ja) 2020-09-13 2023-10-11 アークトゥラス・セラピューティクス・インコーポレイテッド 大型ｒｎａの脂質ナノ粒子封入

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100369593C (zh) * 2002-06-05 2008-02-20 佛罗里达大学研究基金会有限公司 眼科给药体系
DK1599186T3 (da) * 2003-02-24 2013-07-08 Pharmaceutical Productions Inc System til administration af transmukalt lægemiddel
BRPI0412211A (pt) * 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
EP1677758A1 (en) * 2003-10-31 2006-07-12 ALZA Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
KR20090057223A (ko) * 2006-07-31 2009-06-04 센주 세이야꾸 가부시키가이샤 아미드 화합물을 함유하는 수성 액제
SI2481409T1 (sl) * 2007-03-07 2018-09-28 Abraxis Bioscience, Llc Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku
US8974814B2 (en) * 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
WO2009070302A1 (en) * 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
US20090312402A1 (en) * 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
ES2462090T5 (es) * 2008-06-16 2017-07-12 Pfizer Inc. Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method

Also Published As

Publication number Publication date
DOP2015000061A (es) 2015-06-30
NI201500036A (es) 2015-07-16
US20140178475A1 (en) 2014-06-26
PH12015500561A1 (en) 2015-05-11
NZ705985A (en) 2018-08-31
CN104822370A (zh) 2015-08-05
GT201500063A (es) 2019-06-05
PE20150997A1 (es) 2015-07-22
MX363147B (es) 2019-03-11
ECSP15013179A (es) 2015-12-31
HK1211468A1 (en) 2016-05-27
SG11201502008WA (en) 2015-04-29
US20140249158A1 (en) 2014-09-04
EA201590586A1 (ru) 2015-08-31
CR20150189A (es) 2015-09-16
JP2015529683A (ja) 2015-10-08
CA2885022A1 (en) 2014-03-20
MX2015003406A (es) 2015-06-05
BR112015005878A2 (pt) 2017-07-04
EP2895146A1 (en) 2015-07-22
KR20150056619A (ko) 2015-05-26
US20170119672A1 (en) 2017-05-04
US20140248358A1 (en) 2014-09-04
AU2013315125B2 (en) 2018-07-26
JP2018184459A (ja) 2018-11-22
IL237779A0 (en) 2015-05-31
WO2014043625A1 (en) 2014-03-20
AU2013315125A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
CL2015000655A1 (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas
MY196418A (en) Therapeutically Active Compounds and Their Methods of use
CO2018001375A2 (es) Composiciones de retinoides tópicos
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
BR112017016019A2 (pt) método para tratamento de câncer, artigo para fabricação, e, kit.
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX2017015990A (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
MX354383B (es) Sistemas, métodos y formulaciones para tratamiento de cáncer.
CL2014002591A1 (es) Composicion topica semisolida que comprende pirfenidona, dialil oxido de disulfuro modificado (odd-m), un agente gelificante y otros excipientes o aditivos; proceso para fabricarla; metodo de tratamiento; y su uso para eliminar, reducir o prevenir el acne.
NZ710602A (en) Methods for reducing pyrogenicity in a seaweed extract
EP2839833A4 (en) TOPICAL PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPIC TREATMENT OF PSORIASIS, ATOPIAN DERMATITIS OR CHRONIC ECCEM
MX2016004392A (es) Sistema de doble agente de ruptura para reducir daño a la formacion durante la fracturacion.
EP2768824A4 (en) HYBRID DIAZENIUMDIOLATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING CANCER
IL239551A0 (en) Method and device for fiber transport of high-power laser beams
WO2014121020A3 (en) Treatment of psoriasis using helminthic parasite preparations
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
UA69523U (ru) Способ минифлебэктомии при лечении варикозной болезни
IN2013MU02486A (es)